Karyopharm Therapeutics (NASDAQ:KPTI) reported top-line results from its phase III SENTRY trial evaluating selinexor in ...
At this time, I would like to welcome everyone to the Karyopharm Therapeutics' call to discuss top line results from the Phase III SENTRY trial. There will be a question-and-answer session to follow.
Zacks Investment Research on MSN
KPTI stock down on mixed phase III myelofibrosis combo study data
Shares of Karyopharm Therapeutics KPTI plunged 18.3% on Tuesday after the company reported mixed top-line results from a late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results